"Bavarian Nordic shares sink by 12% after mpox sales slump in Q3" was originally created and published by Pharmaceutical ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

GSK), the established players in the RSV vaccine market, had built up sizable inventory, impacting the company’s sales, ...

R-S.C., discusses the Biden administration working with YouTube to censor COVID-19 and vaccine "misinformation" and a bank investigator raising questions over Biden payments. Realtor.com chief ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

RSV vaccine sales were $10 million in the quarter. Cost of Sales: Cost of sales for the third quarter of 2024 was $514 million, which included third-party royalties of $92 million, inventory ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...